Restricted Research - Award List, Note/Discussion Page

Fiscal Year: 2021

366  The University of Texas Rio Grande Valley  (84662)

Principal Investigator: Dentino, Andrew

Total Amount of Contract, Award, or Gift (Annual before 2011): $ 1,161,204

Exceeds $250,000 (Is it flagged?): Yes

Start and End Dates: 10/1/20 - 6/30/21

Restricted Research: YES

Academic Discipline: N/A

Department, Center, School, or Institute: Internal Medicine

Title of Contract, Award, or Gift: CTSA-Convalescent Plasma to Limit Coronavirus Associated Complications. In Covid 19 Hospitalized Patients

Name of Granting or Contracting Agency/Entity: University of Texas Health Science Center at Houston

CFDA: 93.35

Program Title: N/A


This project pertains to an Administrative supplement received by the University of Texas Health Science Center Houston with the goal to bring a large, diverse, COVID-19 positive patient population (thru the resources of the NCATS-supported CTSA) into a randomized, blinded, placebo–controlled Phase Clinical Trial evaluating the efficacy of treatment with convalescent plasma in hospitalized patients. Through the CTSA, UTHealth Houston and Tyler (NE Texas) will enroll a range of diverse patients into this trial. The Department of Internal Medicine at the University of Texas Rio Grande Valley (UTRGV) - School of Medicine will collaborate with the University of Texas Health Science Center Houston to further expand the Center for Clinical and Translational Sciences (CCTS) project by establishing a convalescent plasma trial study at Knapp Medical Center Internal Medicine Clinic in Weslaco. Dr. Dentino will collaborate with UTHSC-Houston to ensure that the CCTS team and members are aware of the progress towards the realization of the study objectives. In addition, Dr. Dentino will have oversight of all Co-Investigators and research staff at the Knapp Medical Center Clinic. SAMs 1.1.8

Discussion: No discussion notes


Close Window